cladribine has been researched along with Minimal Disease, Residual in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (25.00) | 18.2507 |
| 2000's | 16 (40.00) | 29.6817 |
| 2010's | 12 (30.00) | 24.3611 |
| 2020's | 2 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, HH; Jin, LF; Shen, WZ; Zhao, HL; Zhao, M | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Aymerich, M; Baumann, T; Campo, E; Delgado, J; Giné, E; López-Guillermo, A; Magnano, L; Martínez-Trillos, A; Mozas, P; Ortiz-Maldonado, V; Rivas-Delgado, A; Villamor, N | 1 |
| Cecconi, N; Cervetti, G; Galimberti, S; Ghio, F; Pelosini, M; Petrini, M | 1 |
| Kreitman, RJ; Pastan, I | 1 |
| Brandt, M; Burger, J; Chihara, D; Faderl, S; Ferrajoli, A; Jain, P; Jorgensen, J; Kantarjian, H; Keating, M; Luthra, R; O'Brien, S; Pierce, S; Poku, R; Ravandi, F; Thompson, P | 1 |
| Abdel-Wahab, O; Andritsos, LA; Banerji, V; Barrientos, J; Blachly, JS; Call, TG; Catovsky, D; Dearden, C; Demeter, J; Else, M; Falini, B; Forconi, F; Gozzetti, A; Grever, MR; Ho, AD; Johnston, JB; Jones, J; Juliusson, G; Kraut, E; Kreitman, RJ; Larratt, L; Lauria, F; Lozanski, G; Montserrat, E; Parikh, SA; Park, JH; Polliack, A; Quest, GR; Rai, KR; Ravandi, F; Robak, T; Saven, A; Seymour, JF; Tadmor, T; Tallman, MS; Tam, C; Tiacci, E; Troussard, X; Zent, CS; Zenz, T; Zinzani, PL | 1 |
| Baraté, C; Buda, G; Ciancia, E; Galimberti, S; Orciuolo, E; Petrini, M; Sordi, E | 1 |
| Huynh, E; Saven, A; Sigal, D | 1 |
| Burian, C; Saven, A; Sharpe, R; Sigal, DS | 1 |
| Ravandi, F | 1 |
| Tallman, MS | 1 |
| Saven, A; Sigal, DS; Torrey, ML | 1 |
| Brandt, M; Burger, J; Challagundla, P; Faderl, S; Ferrajoli, A; Jorgensen, J; Kantarjian, H; Keating, M; Koller, C; Luthra, R; O'Brien, S; Pierce, S; Ravandi, F; Thomas, D; York, S | 1 |
| Błoński, JZ; Dwilewicz-Trojaczek, J; Góra-Tybor, J; Kasznicki, M; Robak, T; Stella-Hołowiecka, B; Wołowiec, D | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Pralle, H; Schmidt-Wolf, I; Strehl, J; Ziske, C | 1 |
| Bartl, R; Dietzfelbinger, H; Haferlach, T; Heinemann, V; Jehn, U | 1 |
| Andreazzoli, F; Caracciolo, F; Cecconi, N; Cervetti, G; Fazzi, R; Galimberti, S; Petrini, M | 1 |
| Dziecioł, J; Kłoczko, J; Lemancewicz, D; Piszcz, J | 1 |
| Faderl, S; Ferrajoli, A; Freireich, EJ; Giles, FJ; Huang, X; Jones, D; Jorgensen, JL; Kantarjian, HM; Keating, MJ; Koller, CA; O'Brien, SM; Odinga, S; Ravandi, F; Thomas, DA; Verstovsek, S; Wierda, WG | 1 |
| Aschenafi, S; Baur, A; Delacretaz, F; Hsu-Schmitz, SF; Hurwitz, N; Kurrer, M; Mhawech-Fauceglia, P; Oberholzer, M; Von Rohr, A; Wagner, B | 1 |
| Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K | 1 |
| Belani, R; Saven, A | 1 |
| Grever, MR | 1 |
| Bosly, A; Delannoy, A; Deneys, V; Ferrant, A; Gala, JL; Martiat, P; Michaux, JL; Schieff, JM | 1 |
| Carbone, A; Di Celle, PF; Foa, R; Lauria, F; Reato, G | 1 |
| Ellison, DJ; Leopard, JD; Piro, LD; Robbins, BA; Saven, A; Sharpe, RW; Spinosa, JC | 1 |
| Hakimian, D; Peterson, L; Tallman, MS; Wheaton, S | 1 |
| Fend, F; Geisen, F; Hilbe, W; Knoblechner, A; Konwalinka, G; Petzer, A; Schirmer, M; Thaler, J | 1 |
| Machaczka, M; Rucińska, M; Skotnicki, AB; Załuska, A | 1 |
| Delannoy, A; Gala, JL; Guiot, Y; Martiat, P; Philippe, M; Scheiff, JM | 1 |
| Cassileth, PA; Foucar, K; Grever, M; Habermann, T; Hakimian, D; Kopecky, KJ; Peterson, LC; Rowe, JM; Tallman, MS; Wheaton, S; Wollins, E | 1 |
| Krook, JE; Levitt, R; Li, CY; Michalak, JC; Schroeder, G; Tefferi, A; Tschetter, LK; Witzig, TE | 1 |
| Bastie, JN; Castaigne, S; Cazals-Hatem, D; D'Agay, MF; Dabout, D; Daniel, MT; Degos, L; Dombret, H; Flandrin, G; Glaisner, S; Noel-Walter, MP; Poisson, D; Rabian, C | 1 |
| Geisen, F; Grünewald, K; Haun, M; Hilbe, W; Konwalinka, G; Schirmer, M; Thaler, J | 1 |
| Bengio, R; Narbaitz, M; Palacios, F; Sarmiento, M; Scolnik, M | 1 |
| Chrobák, L; Dĕdic, K; Podzimek, K; Zák, P | 1 |
| Celsing, F; Cristiansen, I; Delannoy, A; Johnson, SA; Juliusson, G; Karlsson, K; Kimby, E; Lärfars, G; Liliemark, J; Luthman, M; Nilsson, G; Porwit, A; Strömberg, M; Sundström, G; Tidefelt, U; Wallvik, J | 1 |
| Ghanima, W; Heldal, D; Tjønnfjord, GE | 1 |
11 review(s) available for cladribine and Minimal Disease, Residual
| Article | Year |
|---|---|
CD103-CD23+ classical hair cell leukemia: A case report and review of the literature.
Topics: Antigens, CD; Antineoplastic Agents; Cladribine; Female; Humans; Immunophenotyping; Integrin alpha Chains; Leukemia, Hairy Cell; Middle Aged; Neoplasm, Residual; Receptors, IgE; Rituximab; Treatment Outcome | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Immunoconjugates in the management of hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bacterial Toxins; Cladribine; Clinical Trials as Topic; Exotoxins; Humans; Immunoconjugates; Leukemia, Hairy Cell; Mutation; Neoplasm, Residual; Pentostatin; Peptide Elongation Factor 2; Proto-Oncogene Proteins B-raf; Remission Induction; Survival Analysis | 2015 |
Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Topics: Algorithms; Antineoplastic Agents; Cladribine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Leukemia, Hairy Cell; Models, Biological; Neoplasm, Residual; Purines | 2009 |
Chemo-immunotherapy for hairy cell leukemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Pentostatin; Rituximab | 2011 |
Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Topics: Cladribine; Humans; Immunohistochemistry; Immunophenotyping; Leukemia, Hairy Cell; Neoplasm, Residual | 2011 |
Development of cladribine at Scripps for hairy cell leukemia and current results.
Topics: Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Salvage Therapy; Treatment Outcome | 2011 |
Advances in the treatment of hairy-cell leukaemia.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Cell Adhesion Molecules; Cladribine; Humans; Interferon-alpha; Lectins; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplasms, Second Primary; Pancytopenia; Pentostatin; Receptors, Interleukin-2; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Spleen; Splenectomy; Splenomegaly; Treatment Outcome; Vidarabine | 2003 |
Cladribine in hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Disease-Free Survival; Genes, Immunoglobulin Heavy Chain; Humans; Italy; Leukemia, Hairy Cell; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab; Treatment Outcome | 2006 |
Pentostatin: impact on outcome in hairy cell leukemia.
Topics: Ambulatory Care; Antibiotics, Antineoplastic; Cladribine; Clinical Trials as Topic; Disease-Free Survival; Humans; Leukemia, Hairy Cell; Monitoring, Physiologic; Neoplasm, Residual; Pentostatin; Recurrence | 2006 |
[Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia, Hairy Cell; Neoplasm, Residual; Pentostatin; Remission Induction; Splenectomy; Vidarabine | 1998 |
12 trial(s) available for cladribine and Minimal Disease, Residual
| Article | Year |
|---|---|
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Recurrence; Remission Induction; Rituximab | 2016 |
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Rituximab; Treatment Outcome | 2011 |
Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Opportunistic Infections; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2002 |
Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Cladribine; Combined Modality Therapy; Female; Humans; Hypotension; Immunization, Passive; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Rituximab; Treatment Outcome | 2004 |
Eradication of minimal residual disease in hairy cell leukemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Rituximab | 2006 |
Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Bone Marrow Cells; Cladribine; Follow-Up Studies; Humans; Immunohistochemistry; Injections, Subcutaneous; Leukemia, Hairy Cell; Neoplasm, Residual; Predictive Value of Tests; Remission Induction; Retrospective Studies | 2006 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Neutropenia; Remission Induction | 2006 |
2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Base Sequence; Blotting, Southern; Bone Marrow; Cladribine; Cohort Studies; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Molecular Sequence Data; Neoplasm, Residual; Polymerase Chain Reaction; Remission Induction | 1995 |
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Survival Analysis; United States | 1999 |
Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients, and a long-term follow-up of 126 previously untreated patients.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm, Residual; Opportunistic Infections; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2002 |
17 other study(ies) available for cladribine and Minimal Disease, Residual
| Article | Year |
|---|---|
Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia?
Topics: Adult; Aged; Cladribine; Disease Management; Female; Humans; Immunophenotyping; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Purines; Rituximab | 2018 |
Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Follow-Up Studies; Humans; Immunotherapy; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Rituximab; Splenic Neoplasms; Treatment Outcome | 2013 |
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
Topics: Antineoplastic Agents; Cladribine; Disease Management; Humans; Leukemia, Hairy Cell; Neoplasm Recurrence, Local; Neoplasm, Residual; Pentostatin; Treatment Outcome | 2017 |
Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Clinical Trials, Phase II as Topic; Databases, Factual; Drug Administration Schedule; Female; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Remission Induction; Retrospective Studies; Survivors; Time Factors; Treatment Outcome | 2010 |
An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Cohort Studies; Female; Follow-Up Studies; Humans; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Second Primary; Palliative Care; Pentostatin; Splenectomy; Survival Rate; Treatment Outcome | 2004 |
The influence of chemotherapy on bone marrow in patients with chronic lymphocytic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Bone Marrow; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Vidarabine | 2004 |
Disease eradication in hairy cell leukemia patients treated with 2-chlorodeoxyadenosine.
Topics: Cladribine; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Leukemia, Hairy Cell; Neoplasm, Residual | 1994 |
Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia.
Topics: Antibodies, Monoclonal; Antibody Specificity; Avidin; B-Lymphocyte Subsets; Biopsy, Needle; Biotin; Bone Marrow; Bone Marrow Examination; Cell Membrane; Cell Nucleus; Cladribine; Cytoplasmic Granules; False Negative Reactions; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Hairy Cell; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 1994 |
Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Topics: Antibodies, Monoclonal; Antigens, CD20; Antimetabolites, Antineoplastic; Bone Marrow; Cladribine; Humans; Immunochemistry; Leukemia, Hairy Cell; Neoplasm, Residual; Prognosis; Time Factors | 1996 |
Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Cladribine; Female; Follow-Up Studies; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual | 1995 |
Use of image analysis and immunostaining of bone marrow trephine biopsy specimens to quantify residual disease in patients with B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; B-Lymphocytes; Biopsy; Bone Marrow; Bone Marrow Examination; Cladribine; Female; Flow Cytometry; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Proto-Oncogene Proteins c-bcl-2; Remission Induction | 1999 |
Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow; Cladribine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Pentostatin; Recurrence; Remission Induction | 1999 |
Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; CD4 Lymphocyte Count; Cladribine; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Infections; Interferon-alpha; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Opportunistic Infections; Pentostatin; Remission Induction; Splenectomy; Survival Rate | 1999 |
New rearrangement pattern after treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine.
Topics: Antimetabolites, Antineoplastic; B-Lymphocytes; Blotting, Southern; Cladribine; Clone Cells; Gene Rearrangement, B-Lymphocyte; Genes, Immunoglobulin; Humans; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Remission Induction | 2000 |
[Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Case-Control Studies; Cladribine; Flow Cytometry; Follow-Up Studies; Humans; Immunohistochemistry; Interferon-alpha; Leukemia, Hairy Cell; Neoplasm, Residual; Remission Induction; Sensitivity and Specificity | 2000 |
[Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Cells; Cladribine; Female; Humans; Immunophenotyping; Leukemia, Hairy Cell; Leukemic Infiltration; Male; Middle Aged; Neoplasm, Residual; Remission Induction | 2000 |
[Hairy cell leukemia treated with cladribine].
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Leukemia, Hairy Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies; Remission Induction; Treatment Outcome | 2002 |